| Targeting natural killer cells in cancer immunotherapy C Guillerey, ND Huntington, MJ Smyth Nature immunology 17 (9), 1025-1036, 2016 | 1129 | 2016 |
| FoxO3 regulates neural stem cell homeostasis VM Renault, VA Rafalski, AA Morgan, DAM Salih, JO Brett, AE Webb, ... Cell stem cell 5 (5), 527-539, 2009 | 654 | 2009 |
| TIGIT as an emerging immune checkpoint H Harjunpää, C Guillerey Clinical & Experimental Immunology 200 (2), 108-119, 2020 | 524 | 2020 |
| TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma C Guillerey, H Harjunpää, N Carrié, S Kassem, T Teo, K Miles, ... Blood, The Journal of the American Society of Hematology 132 (16), 1689-1694, 2018 | 284 | 2018 |
| Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment K Nakamura, S Kassem, A Cleynen, ML Chretien, C Guillerey, EM Putz, ... Cancer cell 33 (4), 634-648. e5, 2018 | 208 | 2018 |
| Immunosurveillance and therapy of multiple myeloma are CD226 dependent C Guillerey, LF De Andrade, S Vuckovic, K Miles, SF Ngiow, MCR Yong, ... The Journal of clinical investigation 125 (5), 2077-2089, 2015 | 168 | 2015 |
| Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade SA Minnie, RD Kuns, KH Gartlan, P Zhang, AN Wilkinson, L Samson, ... Blood, The Journal of the American Society of Hematology 132 (16), 1675-1688, 2018 | 163 | 2018 |
| Mitochondrial reactive oxygen species regulate the induction of CD8+ T cells by plasmacytoid dendritic cells M Oberkampf, C Guillerey, J Mouriès, P Rosenbaum, C Fayolle, A Bobard, ... Nature communications 9 (1), 2241, 2018 | 160 | 2018 |
| DNAM-1 expression marks an alternative program of NK cell maturation L Martinet, LF De Andrade, C Guillerey, JS Lee, J Liu, ... Cell reports 11 (1), 85-97, 2015 | 134 | 2015 |
| Eomes-dependent loss of the co-activating receptor CD226 restrains CD8+ T cell anti-tumor functions and limits the efficacy of cancer immunotherapy M Weulersse, A Asrir, AC Pichler, L Lemaitre, M Braun, N Carrié, ... Immunity 53 (4), 824-839. e10, 2020 | 131 | 2020 |
| Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies C Guillerey, K Nakamura, S Vuckovic, GR Hill, MJ Smyth Cellular and Molecular Life Sciences 73, 1569-1589, 2016 | 131 | 2016 |
| NK cells and cancer immunoediting C Guillerey, MJ Smyth Natural killer cells, 115-145, 2016 | 112 | 2016 |
| NK cells in the tumor microenvironment C Guillerey Tumor Microenvironment: Hematopoietic Cells–Part B, 69-90, 2020 | 98 | 2020 |
| Tumor-derived TGFβ alters the ability of plasmacytoid dendritic cells to respond to innate immune signaling M Terra, M Oberkampf, C Fayolle, P Rosenbaum, C Guillerey, G Dadaglio, ... Cancer research 78 (11), 3014-3026, 2018 | 74 | 2018 |
| Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis EM Putz, C Guillerey, K Kos, K Stannard, K Miles, RB Delconte, K Takeda, ... Oncoimmunology 6 (2), e1267892, 2017 | 67 | 2017 |
| Pivotal role of plasmacytoid dendritic cells in inflammation and NK-cell responses after TLR9 triggering in mice C Guillerey, J Mouriès, G Polo, N Doyen, HKW Law, S Chan, P Kastner, ... Blood, The Journal of the American Society of Hematology 120 (1), 90-99, 2012 | 65 | 2012 |
| Inhibitory receptors and immune checkpoints regulating natural killer cell responses to cancer I Buckle, C Guillerey Cancers 13 (17), 4263, 2021 | 61 | 2021 |
| Bone marrow transplantation generates T cell–dependent control of myeloma in mice S Vuckovic, SA Minnie, D Smith, KH Gartlan, TS Watkins, KA Markey, ... The Journal of clinical investigation 129 (1), 106-121, 2019 | 61 | 2019 |
| Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis C Guillerey, MT Chow, K Miles, S Olver, J Sceneay, K Takeda, A Möller, ... Oncoimmunology 4 (9), e1027468, 2015 | 51 | 2015 |
| Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis H Harjunpää, SJ Blake, E Ahern, S Allen, J Liu, J Yan, V Lutzky, K Takeda, ... Oncoimmunology 7 (7), e1445949, 2018 | 48 | 2018 |
